New mRNA flu shot shows promise in older adults
NCT ID NCT06744205
First seen Jun 15, 2026 · Last updated Jun 22, 2026 · Updated 2 times
Summary
This study tested a new mRNA-based flu vaccine in over 1,100 adults aged 50 and older. The vaccine targets two parts of the flu virus (hemagglutinin and neuraminidase) to potentially provide stronger protection. Researchers compared it to standard flu shots and monitored safety and immune response for six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AMR - Chicago- Site Number : 8400012
Oak Brook, Illinois, 60532, United States
-
AMR Las Vegas - Site Number : 8400016
Las Vegas, Nevada, 89119, United States
-
AMR Miami- Site Number : 8400021
Coral Gables, Florida, 33134, United States
-
AMR Mobile- Site Number : 8400022
Mobile, Alabama, 36608, United States
-
Accel Research Site - NeuroStudies.net, LLC - ERN - PPDS- Site Number : 8400001
Decatur, Georgia, 30030-2627, United States
-
Accel Research Sites - Maitland- Site Number : 8400007
Maitland, Florida, 32751, United States
-
Accel Research Sites Network - Birmingham- Site Number : 8400008
Birmingham, Alabama, 35216, United States
-
Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400003
DeLand, Florida, 32720, United States
-
ActivMed Practices & Research- Site Number : 8400005
Methuen, Massachusetts, 03110, United States
-
Alliance for Multispeciality Research - Clinical Research Consortium- Site Number : 8400015
Tempe, Arizona, 85281, United States
-
Alliance for Multispeciality Research - Fort Myers- Site Number : 8400013
Fort Myers, Florida, 33912, United States
-
Alliance for Multispeciality Research - Kansas City- Site Number : 8400019
Kansas City, Missouri, 64114, United States
-
Alliance for Multispeciality Research - Knoxville- Site Number : 8400017
Knoxville, Tennessee, 37920, United States
-
Alliance for Multispeciality Research - Lexington- Site Number : 8400018
Lexington, Kentucky, 40509, United States
-
Alliance for Multispeciality Research - Newton- Site Number : 8400020
Newton, Kansas, 67114, United States
-
Alliance for Multispeciality Research - Wichita East- Site Number : 8400014
Wichita, Kansas, 67207, United States
-
Boston Clinical Trials- Site Number : 8400009
Boston, Massachusetts, 02131, United States
-
Charlottesville Medical Research- Site Number : 8400004
Charlottesville, Virginia, 22911, United States
-
Coastal Carolina Research Center - North Charleston- Site Number : 8400002
North Charleston, South Carolina, 29405, United States
-
Innovation Medical Research Center - Palmetto Bay- Site Number : 8400011
Palmetto Bay, Florida, 33157, United States
-
Investigational Site Number : 0360001
Botany, New South Wales, 2019, Australia
-
Investigational Site Number : 0360002
Melbourne, Victoria, 3124, Australia
-
Investigational Site Number : 0360003
Bayswater, Victoria, 3153, Australia
-
Quest Research Institute- Site Number : 8400010
Farmington Hills, Michigan, 48334, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA influenza vaccine (hexavalent, targeting hemagglutinin and neuraminidase)
What this could lead to
If successful, this could lead to a more effective flu vaccine that offers broader protection for older adults.
What could go wrong
This is an early-phase trial (Phase 1/2) with a relatively small number of participants. The vaccine may not prove more effective than existing flu shots, and side effects are still being evaluated.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.